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correlations, or lack thereof, will be discussed with respect to
general protein ligand interactions and specifically in relation to
drug development. The use of calorimetrically determined thermo-
dynamic data input to decision making in drug development will be
demonstrated.
104-Symp Computational Prediction of
Ligand Binding Modes and Affinities
Johan Aqvist
University Uppsala, Uppsala, Sweden.
Computer simulation has become an increasingly powerful tool for
addressing problems in molecular recognition. Wewill discuss how
the combination of efficient docking procedures with subsequent
binding free energy calculations can be used to predict both binding
modes and affinities with good accuracy and, in particular, recent
results utilizing the linear interaction energy (LIE) method will be
presented. Wewill further address the problems of sensitivity to the
3D receptormodel, discrimination between right andwrong binding
modes, the reliability of empirical scoring functions as well as
mapping of key interactions for the recognition process. Examples
will include both enzyme-inhibitor and ion channel-blocker
complexes.
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105-Symp Extracellular control of
EGF receptor
Kate Ferguson
University Pennsylvania Sch Med, Philadelphia, PA, USA.
It is well accepted that the first step in the activation of receptor
tyrosine kinases (RTKs), such as those of the epidermal growth
factor receptor (EGFR) family, involves ligand-induced receptor
dimerization or alteration of a pre-existing dimers. X-ray crystal
structures of the extracellular region of EGFR (sEGFR) reveal an
unexpected mechanism for ligand-induced dimerization. All of the
contacts across the dimer interface in the sEGFRdimer aremediated
by the receptor, with the majority contributed by domain II. This
contrasts with the case for most other RTKs where the ligand is the
primary mediator of dimer contacts. In unliganded sEGFR the
domain II dimerization interface is occluded in an intramolecular
interaction with domain IV. Ligand binding promotes a dramatic
domain rearrangement in sEGFR, exposing and stabilizing the
domain II dimerization interface. This mechanism has substantial
implication for extracellular control of EGFR activation.
The EGFR family is implicated in several disease states,
perhaps most notably in many cancers. For example, EGFR
activation in epithelial tumors has been linked with more aggres-
sive disease and poorer outcomes. Drugs that inactivate EGFR
through interaction with either the extracellular or intracellular
regions of EGFR are under intense clinical investigation. The
structures of the antigen binding fragments from several thera-
peutic antibodies have been determined in complex with the
extracellular regions of EGFR family members. These structures
indicate several possible mechanisms of inhibition. The structure-
based models for EGFR activation suggest additional modes of
binding that may also be effective. Finally impact of activating
tumor mutations in evaluating the optimal mode of EGFR inhibi-
tion will be discussed.
106-Symp Structural and Mechanistic
Studies of Cancer-causing Mutations
in the EGFR Kinase Reveal A Novel
Mechanism of Drug Resistance
Michael Eck
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Mutations in the EGFR kinase are a cause of non-small cell lung
cancer, and the presence of thesemutations correlates with response
to small-molecule tyrosine kinase inhibitors (TKIs). Interestingly,
some of the mutant kinases are as much as ~100-fold more potently
inhibited by gefitinib and erlotinib than thewild-type kinase, despite
the fact that these TKIs were developed to target the WT enzyme.
Structural studies reveal an altered binding mode of gefitinib in the
L858R mutant, which may in part explain its enhanced sensitivity.
Additionally, kinetic studies show that the L858R and other mutants
have diminished affinity for ATP, rendering them more sensitive to
these ATP-competitive TKIs. Although patients with tumors har-
boring a mutant EGFR initially respond to these drugs, longer-term
efficacy has been limited by the emergence of drug resistance, often
conferred by an additional mutation of Threonine 790 in the EGFR
toMethionine (T790M). This “gatekeeper”mutation lies in the ATP
binding pocket of the kinase, and has been thought to confer
resistance by sterically interfering with drug binding. However, we
show through binding studies, enzyme kinetics, and x-ray crystal-
lography that the T790M mutant and L858R/T7890M double
mutant retain low nanomolar affinity for gefitinib, and that the
T790M mutation does not alter the binding mode of the inhibitors.
Instead, clinically observed drug resistance is due to an increase in
the ATP affinity conferred by the T790M substitution. Since TKIs
must compete with ATP to achieve their intended effect, their
effective potency is diminished by the enhanced ATP-affinity. Thus
the T790M mutation is a “generic” resistance mutation that can be
expected to diminish the potency of any ATP-competitive inhibitor.
Irreversible inhibitors, as a class, overcome this effect through
covalent binding.
107-Symp Role of the Intracellular
Juxtamembrane Region in Activation of
the EGFR
Stuart McLaughlin
SUNY Stony Brook, Stony Brook, NY, USA.
The receptor tyrosine kinase EGFR has an extracellular ligand-
binding domain, a helical transmembrane (TM) domain linked to a
flexible, unfolded juxtamembrane (JM) region, and a kinase do-
main. A popular model of EGFR activation postulates ligand
binding induces dimer formation, permitting the C lobe of one
Meeting-Abstract 33
kinase to bind to the N lobe of the other kinase and activate it
allosterically (Cell, 2006 125, 1030). Recent biophysical experi-
ments, however, suggest EGFR dimers exist in the absence of
ligand: FCS cross correlation (Biophys. J. 2007 93, 684) and
brightness analysis (Biophys. J. 2007 93, 1021) measurements
support prior claims of preformed dimers (e.g., J. Mol. Biol.
2001 311, 1011). Why aren’t these preformed dimers active? We
proposed the JM region, net charge ¼ þ8, binds to acidic lipids on
the inner leaflet of the plasma membrane, which could prevent
contact between kinase domains in a preformed dimer (J Gen
Physiol 2005, 126, 41). This suggests the “Twist model for li-
gand-dependent activation of preformed EGFR dimers” of Gadella
and Jovin (J. Cell Biol. 1995 129, 1543) could be compatible with
the elegant allosteric activation model from the Kuriyan laboratory
(Cell, 2006 125, 1137). A combination of NMR, CD, infrared and
fluorescence measurements on reconstituted TMþ JMEGFR(622–
660) peptides led us to 3 conclusions: the TM helix breaks at the
membrane-solution interface; the unfolded JM region binds elec-
trostatically to the membrane; binding of Ca2þ/calmodulin to the
positively charged JM region can reverse its charge from þ8 to 8
and release it from the membrane (Biochemistry 2006, 45, 12704).
Any factor that reduces the electrostatic interaction of the JM region
with the plasma membrane should activate EGFR in the absence of
ligand (J. Biol. Chem. 2007 282, 8474).
Platform J: Self-Assembled-Session: The Hidden
Photophysics of Autofluorescent Proteins
108-Plat From the knowledge of
protonation ground states to the
development of photochromic Green
Fluorescent Proteins
Ranieri Bizzarri1,2, Cristiano Viappiani3, Michela Serresi1,
Stefania Abbruzzetti3, Stefano Luin1, Valerio Voliani1,
Riccardo Nifosı`2, Elena Grandi3, Fabio Beltram1,2
1 Scuola Normale Superiore, IIT Udr, Pisa, Italy
2 Scuola Normale Superiore, NEST CNR-INFM, Pisa, Italy
3Dipartimento di Fisica, Universita di Parma, NEST CNR-INFM, Parma,
Italy.
Autofluorescent proteins (FPs), and particularly Green Fluorescent
Proteins mutants (GFPs), have revolutionized biophysical and
molecular biology studies owing to the genetic encoding of strong
visible fluorescence in vivo (1). The optical properties of FPs
originate from an organic emitter molecule buried inside a higly-
ordered b-can tertiary structure. The engineering of FPs’ optical
properties by means of sequence mutation allows to obtain probes
tailored for high-resolution intracellular studies.
Recently, scientific attention has been attracted by “hidden”
photophysical properties of FPs (2). In this field, we have been
involved in the development and application of photochromic GFPs
mutants since 2001 (3–5) and we have shown that pH-dependent
optical properties of most GFP mutants can be described by a
general two-site ionization model (6). This model helped us to
develop new ratiometric pH biosensors for intracellular use (7).
Here, we shall show how the knowledge of the protonation ground
states led us to generate new photochromic GFP mutants. Quanti-
tative details on the photophysical mechanism underlying the
observed photochromic behavior will be reported.
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109-Plat Pa-GFP Photoactivation
Kinetics In Model And Cell Systems
Ilaria Testa1, Davide Mazza1, Francesca Cella1,
Emiliano Ronzitti1, Sara Barozzi2, Mario Faretta2,
Alberto Diaspro1
1LAMBSMicroScoBio,Department of Physics-University ofGenoa,Genoa,
Italy
2 IEO-IFOM Consortium for Oncogenomics, Milan, Italy.
We present data related to the possibility to induce the photo-
activation process on the photo-activatable green fluorescent pro-
tein paGFP, T203 variant (1), at different wavelengths, specifically
in the (270–488) nm spectral range under linear conditions and in
the infrared range under multi-photon absorption (2). In particular,
exploiting UV irradiation to bring the molecules in the activated
state it is possible to evaluate the absorption properties of activated
and non activated form of the fluorescent protein in solution,
without additional artefacts due to photobleaching or environmen-
tal conditions. These results were employed to separate the con-
tribution of the two forms of the molecules via a home made linear
unmixing algorithm. This analysis allowed to identify the kinetic
behaviour of activated and non activated paGFP populations in
more complex systems, like proteins layers and fixed cells while
utilizing confocal and two-photon microscopy. In particular, a
different fraction of molecules undergoing photoactivation was
found depending on the energy delivered during the activation step.
We demonstrate that this phenomenon is driven by the competition
of photoactivation and photobleaching of the pre- and post-acti-
vated form of paGFPs.
In conclusion, we showed unreported photoactivation pathways
of the proteins in the UV range that were useful for the comprehen-
sion of the nature and kinetics of photobleaching and photoactiva-
tion processes. These results are in tune with the broadening of two
photon activation spectra (2) and with blue-photoactivation path-
ways (3) early reported.
(Grants MiUR PRIN2006, IFOM Milan)
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